Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:21 PM
Ignite Modification Date:
2025-12-24 @ 10:21 PM
NCT ID:
NCT01795235
Eligibility Criteria:
Inclusion Criteria:
1. Healthy normal men
2. Age 18-30 yrs
3. BMI 18-27 kg/m2
Exclusion Criteria:
1. Medication or previous surgery known to affect ghrelin secretion.
2. Medications known to have an impact on body weight (Seroquel, tricyclic antidepressants).
3. Medications known to have an impact on the beta adrenergic system.
4. Coronary artery disease, congestive heart failure, peripheral vascular disease, diabetes mellitus, significant hypertension (BP \>180 systolic or \>100 diastolic at rest); renal, hepatic, pulmonary disease; untreated hypothyroidism, untreated hyperthyroidism; history of seizure disorder; history of malignancy (other than some skin cancers), history of active chronic infections (e.g., HIV, tuberculosis).
5. Endocrine disorders, i.e., pheochromocytoma, adrenal insufficiency
6. Hematocrit \< 41% men
7. History of daily tobacco use within past 3 months
8. Chronic alcohol abuse by history
9. Weight not stable (more than 10% weight change or more over past 6 months)
10. Strenuous exercise for average of more than 60 min/day
11. Investigational drug within past 6 weeks
12. Psychiatric history especially eating disorders
13. Transmeridian travel within 2 weeks prior to or during study
14. Known hypersensitivity to beta-blockers
15. Estimated Glomerular Filtration Rate below 60 mL/min/1.73m2.
16. Known cardiac dysrhythmia, especially first degree heart block. -
Healthy Volunteers:
True
Sex:
MALE
Minimum Age:
18 Years
Maximum Age:
30 Years
Study:
NCT01795235
Study Brief:
Protocol Section:
NCT01795235